EverHint — Insider Trading Radar (November 13, 2025)

November 13, 2025

Scope: Highlights from today’s Form 4s with emphasis on open-market buys/sells and any 10%-owner moves. Each item includes quick, recent context from company news.

10%-Owner & Control-Level Activity

CRVO — CervoMed
Who: John J. Alam (Director, 10% owner) & Sylvie Grégoire (Director, 10% owner)
What: Buys 5,553 @ $7.35 each (≈$40.8K apiece), 11/12 → SEC Form 4 (issuer indexes)
Context: Lands after Nov 10 update: company announced alignment with FDA on next clinical steps. (ir.cervomed.com)

TPL — Texas Pacific Land
Who: Horizon Kinetics Asset Management (10% owner)
What: Buy 1 @ $996.33 ($996), 11/12 → SEC Form 4 (issuer index)
Context: De-minimis add by a long-time major holder.

Notable Insider Buys (Open-Market)

PRMB — Primo Brands

• Eric J. Foss (Exec. Chair & CEO, Director, 10% owner): Buys 123,049 @ $15.52 (≈$1.91M) on 11/11 and 4,970 @ $16.15 (≈$80K) on 11/12 → SEC Form 4 (issuer index)
  Context: Large, back-to-back C-suite purchases; several recent notes discuss early post-earnings positioning. (SEC)

CLVT — Clarivate

• Kenneth L. Cornick (Director): Buy 100,000 @ $3.45 ($345K), 11/10 → SEC Form 4
  Context: Follows Q3 2025 results and ongoing share repurchases reported Oct 29. (ir.clarivate.com)

ARQ — Arq, Inc.

• Richard Campbell-Breeden (Director): Buy 28,638 @ $3.54 ($101.5K), 11/11
• Jay L. Voncannon (CFO): Buys 9,000 @ $3.74 ($33.7K) on 11/10 and 6,000 @ $3.55 ($21.3K) on 11/11 → SEC Form 4 (issuer indexes)
  Context: Clustered accumulation flagged today; coverage notes recent price weakness. (Investing.com)

CRVO — CervoMed

• William R. Elder (CFO): Buy 3,500 @ $7.44 ($26.0K), 11/12 → SEC Form 4
  Context: Adds to today’s director/10%-owner buys and comes right after the FDA alignment disclosure. (Investing.com)

BW — Babcock & Wilcox

• Cameron M. Frymyer (CFO): Buy 2,853 @ $7.05 ($20.1K), 11/12 → SEC Form 4
  Context: Follows Nov 7 update that B&W raised $67.5M via ATM and Nov 4 Q3 results incl. AI data-center project commentary. (Babcock & Wilcox Investor Relations)

Notable Insider Sells (Open-Market)

LH — Labcorp

• Adam H. Schechter (Chair & CEO): Sale 5,745 @ $262.75 (≈$1.51M), 11/11 → SEC Form 4
  Context: Stock rallied post-late-Oct print when Labcorp raised FY25 profit outlook; dividend payable Dec 11. (Reuters)

OMF — OneMain Holdings

• Micah R. Conrad (EVP & COO): Sale 5,000 @ $59.20 ($296K), 11/07 → SEC Form 4
  Context: Sale disclosed today; shares have held gains following Q3 and ongoing capital-return updates. (Investing.com)

RBC — RBC Bearings

• Steven H. Kaplan (Director): Sale 500 @ $442.86 ($221.4K), 11/12 → SEC Form 4
  Context: Arrives ~two weeks after Q2 FY26 results that beat on revenue and EPS. (investor.rbcbearings.com)

PFG — Principal Financial Group

• Wee Yee Cheong (Officer): Sale 1,887 @ $85.04 ($160K), 11/12 → SEC Form 4
  Context: Recent headlines highlighted dividend/buyback cadence around Q3. (investors.principal.com)

ITGR — Integer Holdings

• Tommy P. Thomas (EVP): Sale 884 @ $70.15 ($62.0K), 11/11 → SEC Form 4
  Context: Small sale after Q3 beat and a $200M repurchase authorization (Nov 4). (Integer Holdings Corporation)

LCNB — LCNB Corp.

• William G. Huddle (Director): Sale 3,000 @ $15.51 ($46.5K), 11/12 → SEC Form 4
  Context: Community bank with forward dividend yield near ~5.7%; recent updates reiterate the $0.22 quarterly payout cadence. (StockAnalysis)

Quick Take

• High-signal buy: PRMB — near-$2M CEO purchase over two days stands out for size/timing. Constructive pending follow-through. (SEC)
• Biotech cluster: CRVO shows a coordinated set of insider buys days after an FDA-alignment update—positive read-through for near-term confidence. (ir.cervomed.com)
• Turnaround/watch: ARQ insiders (director + CFO) adding into weakness could be a sentiment reset if buying persists. (Investing.com)
• Post-print trims: LH, RBC, PFG, ITGR sales look routine against recently improved fundamentals or capital-return headlines; monitor for patterns rather than one-offs. (Reuters)

Method: We prioritize open-market Form 4s (codes P/S) and material 10%-owner moves, excluding routine awards, gifts, and tax-withholding entries. Dollar values = reported shares × price in the filings. Dates shown are transaction dates.

Independent research. No hype, no pumps, no paid promotions — just clean, data-driven signals and concise context.